查看购物车
  • Traditional Chinese
  • English
  • Japanese
2021-2031年北美胃肠药物市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819717

2021-2031年北美胃肠药物市场报告（范围、细分、动态和竞争分析）

North America Gastrointestinal Drugs Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 155 Pages | 订单完成后即时交付

价格

北美胃肠药物市场预计将大幅成长，到 2031 年将达到 433.6258 亿美元，高于 2023 年的 241.044 亿美元。这一成长代表着 2023 年至 2031 年的年复合成长率(CAGR) 为 7.6%。

执行摘要和市场分析

北美胃肠药物市场主要分为三个区域：美国、加拿大和墨西哥。推动该市场成长的因素包括：生活方式改变导致的胃肠疾病发病率上升、政府出台的预防和治疗胃肠疾病的倡议、健全的医疗基础设施、蓬勃发展的製药行业、全面的报销覆盖范围以及大型製药公司的参与。

市场区隔分析

北美胃肠药物市场可以透过各个部分进行分析，包括药物类别、应用、给药途径和配销通路。

1. 药品类别：市场分为几类，包括生物製剂、止泻药、泻药、酸中和剂、抗发炎药、止吐药和止吐药等。 2023年，生物製剂占据了最大的市场份额，反映出其在治疗胃肠道疾病的重要性日益增强。

2. 应用：市场也按应用细分，包括肠躁症 (IBS)、发炎性肠道疾病 (IBD)（例如溃疡性结肠炎和克隆氏症）、胃肠炎、乳糜泻等。 2023 年，IBS 细分市场占据最大份额，显示针对该疾病的治疗需求庞大。

3. 给药途径：胃肠药物市场分为口服和非肠道给药途径。 2023年，口服药物占据市场主导地位，因为口服药物因其便捷易用而更受青睐。

4.配销通路：胃肠药物的分销分为医院药房、零售药房和线上药房。 2023年，医院药局占据了最大的市场份额，凸显了医院在药物分配方面的关键作用。

市场展望

近年来，先进疗法，尤其是生物製剂的研发蓬勃发展，越来越多地用于治疗发炎性疾病。生物製剂彻底改变了发炎性肠道疾病 (IBD) 的治疗格局，其成功也促进了其在其他胃肠道疾病的应用。这些药物针对免疫系统中导致疾病的特定成分，使其对嗜酸性食道炎、乳糜泻和自体免疫性肝炎等疾病有效。

生物製剂，尤其是抗肿瘤坏死因子 (TNF) 药物，在溃疡性结肠炎和克隆氏症的治疗中发挥关键作用。这些药物包括修美乐 (Humira)、辛普尼 (Simponi) 和雷米克 (Remicade) 等知名药物，其作用机制是阻断肿瘤坏死因子-α (TNF-α)，一种促进发炎的蛋白质。这些生物製剂的引入显着改善了发炎性肠道疾病 (IBD) 的治疗，许多患者透过使用这些药物获得了缓解。 FDA 已批准多种用于治疗 IBD 的生物製剂，包括修美乐 (Humira)、欣舒利 (Cimzia)、辛普尼 (Simponi)、泰萨布里 (Tysabri)、雷米克 (Remicade)、恩蒂维奥 (Entyvio) 和斯特拉拉 (Stelara)。值得注意的是，维多珠单抗已成为中度至重度克隆氏症和溃疡性结肠炎的首选二线生物製剂。

2024年2月，Celltrion Healthcare的Remsima SC获得加拿大卫生部批准，用于发炎性肠道疾病（IBD）的维持治疗，进一步彰显了该领域的持续创新。发展中国家胃肠道疾病的发生率不断上升，也推动了对新型生物製剂的需求，从而促进了市场成长。

国家洞察

从地理来看，北美胃肠药物市场主要由美国、加拿大和墨西哥组成，其中美国在2023年占据最大市场份额。美国胃肠疾病盛行率的上升是推动此类药物需求的重要因素。克隆氏症和溃疡性结肠炎等疾病特别常见，根据美国克隆氏症和结肠炎基金会的数据，每年约有7万例新诊断病例。发炎性肠道疾病（IBD）的总体盛行率从2011年到2020年显着上升，估计约有240万美国人受到影响。

预计胃肠道疾病研发资金的增加将加强对新型治疗方案的关注。例如，克隆氏症研究在2022年获得了9,000万美元的资助，彰显了推动治疗方案的承诺。

美国FDA核准的新药也有望促进市场成长。例如，2020年5月，FDA核准Qinlock用于治疗晚期胃肠道间质瘤；2024年5月，Strides Pharma获得核准，其仿製药Sucralfate口服混悬液可用于治疗多种胃肠道疾病。

公司简介

北美胃肠药物市场的主要参与者包括赛诺菲公司、葛兰素史克公司、强生公司、博士伦公司、阿斯特捷利康公司、武田製药有限公司、艾伯维公司、拜耳公司、Celltrion公司和辉瑞公司。这些公司正在采用各种策略，包括扩张、产品创新和併购，以增强其市场占有率并为消费者提供创新解决方案。

目录

第一章：简介

第二章：执行摘要

  • 关键见解

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：

第四章：北美胃肠药物市场格局

  • 概述
  • PEST分析

第五章：北美胃肠药物市场-关键市场动态

  • 市场驱动因素
    • 胃肠道疾病病例增加
    • 生物製剂的不断发展
  • 市场限制
    • 生物製剂成本高
    • 治疗严重溃疡性结肠炎或克隆氏症的生物製剂平均费用
  • 市场机会
    • 公司的策略倡议
  • 未来趋势
    • 加大对新药开发与人工智慧技术的研究投入
  • 驱动因素和限制因素的影响：

第六章：胃肠药物市场－北美分析

  • 2021-2031年北美胃肠药物市场收入

第七章：北美胃肠药物市场分析－依药物类别

  • 生物製剂
  • 止泻药和泻药
  • 酸中和剂
  • 抗发炎药物
  • 止吐药和止噁心药
  • 其他的

第 8 章：北美胃肠药物市场分析 - 按应用

  • 急躁性肠症候群
  • 发炎性溃疡性结肠炎
  • 克罗恩病
  • 胃肠炎
  • 乳糜泻
  • 其他的

第九章：北美胃肠药物市场分析-依给药途径

  • 口服
  • 肠外

第 10 章：北美胃肠药物市场分析 - 按配销通路

  • 医院药房
  • 零售药局
  • 网路药局

第 11 章：北美胃肠药物市场-国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 12 章：产业格局

  • 概述
  • 北美胃肠药物市场的成长策略
  • 有机成长策略
    • 概述
  • 无机成长策略
    • 概述

第十三章：公司简介

  • Sanofi SA
  • GSK Plc
  • Johnson & Johnson
  • Bausch Health Companies Inc
  • AstraZeneca Plc
  • Takeda Pharmaceutical Co Ltd
  • AbbVie Inc
  • Bayer AG
  • Celltrion Inc
  • Pfizer Inc

第 14 章：附录

Product Code: TIPRE00016278

The North America gastrointestinal drugs market is projected to grow significantly, reaching an estimated US$ 43,362.58 million by 2031, up from US$ 24,104.40 million in 2023. This growth represents a compound annual growth rate (CAGR) of 7.6% from 2023 to 2031.

Executive Summary and Market Analysis

The gastrointestinal drugs market in North America is divided into three primary regions: the United States, Canada, and Mexico. Several factors are driving the growth of this market, including the rising incidence of gastrointestinal disorders linked to lifestyle changes, government initiatives aimed at the prevention and treatment of these diseases, a robust healthcare infrastructure, a thriving pharmaceutical sector, comprehensive reimbursement coverage, and the presence of major pharmaceutical companies.

Market Segmentation Analysis

The North America gastrointestinal drugs market can be analyzed through various segments, including drug class, application, route of administration, and distribution channel.

1. Drug Class: The market is categorized into several drug classes, including biologics, antidiarrheal and laxatives, acid neutralizers, anti-inflammatory drugs, antiemetic and antinauseants, among others. In 2023, biologics accounted for the largest market share, reflecting their growing importance in treating gastrointestinal conditions.

2. Application: The market is also segmented by application, which includes conditions such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) like ulcerative colitis and Crohn's disease, gastroenteritis, celiac disease, and others. The IBS segment held the largest share in 2023, indicating a significant demand for treatments targeting this condition.

3. Route of Administration: The gastrointestinal drugs market is divided into oral and parenteral routes of administration. The oral segment dominated the market in 2023, as oral medications are often preferred for their convenience and ease of use.

4. Distribution Channel: The distribution of gastrointestinal drugs is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies represented the largest share of the market in 2023, highlighting the critical role of hospitals in dispensing these medications.

Market Outlook

Recent years have seen a surge in the development of advanced treatments, particularly biologics, which are increasingly used for managing inflammatory diseases. Biologics have revolutionized the treatment landscape for inflammatory bowel diseases (IBD), and their success has encouraged their application in other gastrointestinal disorders. These drugs target specific elements of the immune system that contribute to disease, making them effective for conditions such as eosinophilic esophagitis, celiac disease, and autoimmune hepatitis.

Biologics, particularly anti-TNF agents, have been pivotal in managing ulcerative colitis and Crohn's disease. These agents, which include well-known medications like Humira, Simponi, and Remicade, work by blocking tumor necrosis factor-alpha (TNF-alpha), a protein that promotes inflammation. The introduction of these biologics has significantly improved the management of IBD, with many patients achieving remission through their use. The FDA has approved numerous biologic drugs for IBD treatment, including Humira, Cimzia, Simponi, Tysabri, Remicade, Entyvio, and Stelara. Notably, Vedolizumab has emerged as a preferred second-line biologic for moderate to severe cases of Crohn's disease and ulcerative colitis.

In February 2024, Celltrion Healthcare's Remsima SC received approval from Health Canada for maintenance therapy in IBD, further illustrating the ongoing innovation in this field. The increasing prevalence of gastrointestinal diseases in developing countries is also driving the demand for new biologics, contributing to market growth.

Country Insights

Geographically, the North American gastrointestinal drugs market is primarily composed of the US, Canada, and Mexico, with the US holding the largest market share in 2023. The rising prevalence of gastrointestinal diseases in the US is a significant factor driving demand for these drugs. Conditions such as Crohn's disease and ulcerative colitis are particularly prevalent, with approximately 70,000 new cases diagnosed annually, according to the Crohn's & Colitis Foundation of America. The overall prevalence of IBD has increased notably from 2011 to 2020, with estimates suggesting that around 2.4 million Americans are affected.

Increased funding for research and development in gastrointestinal diseases is expected to enhance the focus on novel treatment options. For instance, Crohn's disease research received US$ 90 million in funding in 2022, underscoring the commitment to advancing treatment options.

The US FDA's approval of new drugs is also anticipated to bolster market growth. For example, in May 2020, the FDA approved Qinlock for advanced gastrointestinal stromal tumors, and in May 2024, Strides Pharma received approval for a generic version of Sucralfate Oral Suspension for various gastrointestinal conditions.

Company Profiles

Key players in the North America gastrointestinal drugs market include Sanofi SA, GSK Plc, Johnson & Johnson, Bausch Health Companies Inc, AstraZeneca Plc, Takeda Pharmaceutical Co Ltd, AbbVie Inc, Bayer AG, Celltrion Inc, and Pfizer Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their market presence and offer innovative solutions to consumers.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. North America Gastrointestinal Drugs Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Gastrointestinal Drugs Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Cases of Gastrointestinal Diseases
    • 5.1.2 Increasing Development of Biologics
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Biologics
    • 5.2.2 Average Cost of Biologic Drugs for Severe Ulcerative Colitis or Crohn's Disease
  • 5.3 Market Opportunities
    • 5.3.1 Strategic Initiatives by Companies
  • 5.4 Future Trends
    • 5.4.1 Increasing Research Investment for Novel Drug Development and Artificial Intelligence-Based Techniques
  • 5.5 Impact of Drivers and Restraints:

6. Gastrointestinal Drugs Market - North America Analysis

  • 6.1 North America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031

7. North America Gastrointestinal Drugs Market Analysis - by Drug Class

  • 7.1 Biologics
    • 7.1.1 Overview
    • 7.1.2 Biologics: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.2 Antidiarrheal and Laxatives
    • 7.2.1 Overview
    • 7.2.2 Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.3 Acid Neutralizers
    • 7.3.1 Overview
    • 7.3.2 Acid Neutralizers: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.4 Anti-inflammatory Drugs
    • 7.4.1 Overview
    • 7.4.2 Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.5 Antiemetic and Antinauseants
    • 7.5.1 Overview
    • 7.5.2 Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

8. North America Gastrointestinal Drugs Market Analysis - by Application

  • 8.1 Irritable Bowel Syndrome
    • 8.1.1 Overview
    • 8.1.2 Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.2 Inflammatory Ulcerative Colitis
    • 8.2.1 Overview
    • 8.2.2 Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.3 Crohn's Disease
    • 8.3.1 Overview
    • 8.3.2 Crohn's Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.4 Gastroenteritis
    • 8.4.1 Overview
    • 8.4.2 Gastroenteritis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.5 Celiac Disease
    • 8.5.1 Overview
    • 8.5.2 Celiac Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

9. North America Gastrointestinal Drugs Market Analysis - by Route of Administration

  • 9.1 Oral
    • 9.1.1 Overview
    • 9.1.2 Oral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 9.2 Parenteral
    • 9.2.1 Overview
    • 9.2.2 Parenteral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

10. North America Gastrointestinal Drugs Market Analysis - by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Overview
    • 10.1.2 Hospital Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.2 Retail Pharmacies
    • 10.2.1 Overview
    • 10.2.2 Retail Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • 10.3 Online Pharmacies
    • 10.3.1 Overview
    • 10.3.2 Online Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)

11. North America Gastrointestinal Drugs Market - Country Analysis

  • 11.1 North America
    • 11.1.1 North America Gastrointestinal Drugs Market Overview
    • 11.1.2 North America Gastrointestinal Drugs Market - Breakdown, by Key Countries, 2023 and 2031 (%)
      • 11.1.2.1 United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.1.1 United States: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.1.2 United States: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.1.3 United States: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.1.4 United States: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.2.2 Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.2.1 Canada: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.2.2 Canada: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.2.3 Canada: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.2.4 Canada: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel
      • 11.1.2.3 Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
        • 11.1.2.3.1 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Drug Class
        • 11.1.2.3.2 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Application
        • 11.1.2.3.3 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Route Of Administration
        • 11.1.2.3.4 Mexico: North America Gastrointestinal Drugs Market Breakdown, by Distribution Channel

12. Industry Landscape

  • 12.1 Overview
  • 12.2 Growth Strategies in North America Gastrointestinal Drugs Market
  • 12.3 Organic Growth Strategies
    • 12.3.1 Overview
  • 12.4 Inorganic Growth Strategies
    • 12.4.1 Overview

13. Company Profiles

  • 13.1 Sanofi SA
    • 13.1.1 Key Facts
    • 13.1.2 Business Description
    • 13.1.3 Products and Services
    • 13.1.4 Financial Overview
    • 13.1.5 SWOT Analysis
    • 13.1.6 Key Developments
  • 13.2 GSK Plc
    • 13.2.1 Key Facts
    • 13.2.2 Business Description
    • 13.2.3 Products and Services
    • 13.2.4 Financial Overview
    • 13.2.5 SWOT Analysis
    • 13.2.6 Key Developments
  • 13.3 Johnson & Johnson
    • 13.3.1 Key Facts
    • 13.3.2 Business Description
    • 13.3.3 Products and Services
    • 13.3.4 Financial Overview
    • 13.3.5 SWOT Analysis
    • 13.3.6 Key Developments
  • 13.4 Bausch Health Companies Inc
    • 13.4.1 Key Facts
    • 13.4.2 Business Description
    • 13.4.3 Products and Services
    • 13.4.4 Financial Overview
    • 13.4.5 SWOT Analysis
    • 13.4.6 Key Developments
  • 13.5 AstraZeneca Plc
    • 13.5.1 Key Facts
    • 13.5.2 Business Description
    • 13.5.3 Products and Services
    • 13.5.4 Financial Overview
    • 13.5.5 SWOT Analysis
    • 13.5.6 Key Developments
  • 13.6 Takeda Pharmaceutical Co Ltd
    • 13.6.1 Key Facts
    • 13.6.2 Business Description
    • 13.6.3 Products and Services
    • 13.6.4 Financial Overview
    • 13.6.5 SWOT Analysis
    • 13.6.6 Key Developments
  • 13.7 AbbVie Inc
    • 13.7.1 Key Facts
    • 13.7.2 Business Description
    • 13.7.3 Products and Services
    • 13.7.4 Financial Overview
    • 13.7.5 SWOT Analysis
    • 13.7.6 Key Developments
  • 13.8 Bayer AG
    • 13.8.1 Key Facts
    • 13.8.2 Business Description
    • 13.8.3 Products and Services
    • 13.8.4 Financial Overview
    • 13.8.5 SWOT Analysis
    • 13.8.6 Key Developments
  • 13.9 Celltrion Inc
    • 13.9.1 Key Facts
    • 13.9.2 Business Description
    • 13.9.3 Products and Services
    • 13.9.4 Financial Overview
    • 13.9.5 SWOT Analysis
    • 13.9.6 Key Developments
  • 13.10 Pfizer Inc
    • 13.10.1 Key Facts
    • 13.10.2 Business Description
    • 13.10.3 Products and Services
    • 13.10.4 Financial Overview
    • 13.10.5 SWOT Analysis
    • 13.10.6 Key Developments

14. Appendix

  • 14.1 About The Insight Partners
  • 14.2 Glossary of Terms

List Of Tables

  • Table 1. North America Gastrointestinal Drugs Market Segmentation
  • Table 2. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 3. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 4. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 5. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 6. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 7. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 8. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 9. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 10. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Drug Class
  • Table 11. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Application
  • Table 12. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Route Of Administration
  • Table 13. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million) - by Distribution Channel
  • Table 14. Recent Organic Growth Strategies in North America Gastrointestinal Drugs Market
  • Table 15. Recent Inorganic Growth Strategies in the North America Gastrointestinal Drugs Market
  • Table 16. Glossary of Terms, North America Gastrointestinal Drugs Market

List Of Figures

  • Figure 1. North America Gastrointestinal Drugs Market Segmentation, by Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Gastrointestinal Drugs Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Gastrointestinal Drugs Market Revenue (US$ Million), 2021-2031
  • Figure 6. North America Gastrointestinal Drugs Market Share (%) - by Drug Class (2023 and 2031)
  • Figure 7. Biologics: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 8. Antidiarrheal and Laxatives: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 9. Acid Neutralizers: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 10. Anti-inflammatory Drugs: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 11. Antiemetic and Antinauseants: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 12. Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 13. North America Gastrointestinal Drugs Market Share (%) - by Application (2023 and 2031)
  • Figure 14. Irritable Bowel Syndrome: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 15. Inflammatory Ulcerative Colitis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 16. Crohn's Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 17. Gastroenteritis: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 18. Celiac Disease: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 19. Others: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 20. North America Gastrointestinal Drugs Market Share (%) - by Route Of Administration (2023 and 2031)
  • Figure 21. Oral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 22. Parenteral: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 23. North America Gastrointestinal Drugs Market Share (%) - by Distribution Channel (2023 and 2031)
  • Figure 24. Hospital Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 25. Retail Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 26. Online Pharmacies: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031 (US$ Million)
  • Figure 27. North America Gastrointestinal Drugs Market Breakdown, by Key Countries - Revenue (2023) (US$ Million)
  • Figure 28. North America Gastrointestinal Drugs Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 29. United States: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 30. Canada: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 31. Mexico: North America Gastrointestinal Drugs Market - Revenue and Forecast to 2031(US$ Million)
  • Figure 32. Growth Strategies in North America Gastrointestinal Drugs Market